Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Wordsworth

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
Personalized Medicine|August 14, 2023
Budget impact and transferability of cost-effectiveness of <i>DPYD</i> testing in metastatic breast cancer in three health systemsRositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, et al.
Lancet (London, England)|July 5, 2025
Stereotactic radiotherapy for nAMD: areas for improvement - Authors' replyTimothy L Jackson, Helen Dakin, Xuemin Zhu, et al.
Personalized Medicine|September 4, 2023
Cost-effectiveness of extended <i>DPYD</i> testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UKRositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, et al.
Family Practice|June 22, 2006
Cluster randomized trial of a multifaceted primary care decision-support intervention for inherited breast cancer riskBrenda J Wilson, Nicola Torrance, Jill Mollison, et al.
Genomic Medicine|October 17, 2008
Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United KingdomSarah Wordsworth, James Buchanan, Regina Regan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 13, 2022
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy EntrectinibSimone Huygens, Heleen Vellekoop, Matthijs Versteegh, et al.
Applied Health Economics and Health Policy|April 4, 2022
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future OptionsRositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 2, 2023
Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in AustraliaChi Kin Law, Anne E Cust, Amelia K Smit, et al.
BMC Public Health|March 17, 2026
Social impact bonds: opportunities for funding health promotion and disease preventionStefánia Plankó, Emily Hulse, Maureen Rutten-van Mölken, et al.
Communications Medicine|May 25, 2024
Overcoming challenges in the economic evaluation of interventions to optimise antibiotic useLaurence S J Roope, Liz Morrell, James Buchanan, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Personalized Medicine|August 14, 2023
Budget impact and transferability of cost-effectiveness of <i>DPYD</i> testing in metastatic breast cancer in three health systemsRositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, et al.
Lancet (London, England)|July 5, 2025
Stereotactic radiotherapy for nAMD: areas for improvement - Authors' replyTimothy L Jackson, Helen Dakin, Xuemin Zhu, et al.
Personalized Medicine|September 4, 2023
Cost-effectiveness of extended <i>DPYD</i> testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UKRositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, et al.
Family Practice|June 22, 2006
Cluster randomized trial of a multifaceted primary care decision-support intervention for inherited breast cancer riskBrenda J Wilson, Nicola Torrance, Jill Mollison, et al.
Genomic Medicine|October 17, 2008
Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United KingdomSarah Wordsworth, James Buchanan, Regina Regan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 13, 2022
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy EntrectinibSimone Huygens, Heleen Vellekoop, Matthijs Versteegh, et al.
Applied Health Economics and Health Policy|April 4, 2022
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future OptionsRositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 2, 2023
Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in AustraliaChi Kin Law, Anne E Cust, Amelia K Smit, et al.
BMC Public Health|March 17, 2026
Social impact bonds: opportunities for funding health promotion and disease preventionStefánia Plankó, Emily Hulse, Maureen Rutten-van Mölken, et al.
Communications Medicine|May 25, 2024
Overcoming challenges in the economic evaluation of interventions to optimise antibiotic useLaurence S J Roope, Liz Morrell, James Buchanan, et al.
Pageof 15